The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

被引：175

作者：

Banerji, Udai ^{[1
]}

Camidge, D. Ross ^{[2
]}

Verheul, Henk M. W. ^{[3
]}

Agarwal, Roshan

Sarker, Debashis

Kaye, Stan B.

Desar, Ingrid M. E. ^{[4
]}

Timmer-Bonte, Johanna N. H. ^{[4
]}

Eckhardt, S. Gail ^{[2
]}

Lewis, Karl D. ^{[2
]}

Brown, Kathryn H. ^{[5
]}

Cantarini, Mireille V. ^{[5
]}

Morris, Clive ^{[5
]}

George, Sarah M. A. ^{[5
]}

Smith, Paul D. ^{[5
]}

van Herpen, Carla M. L. ^{[4
]}

机构：

[1] Royal Marsden Hosp, Inst Canc Res, Drug Dev Unit, Sutton SM2 5PT, Surrey, England

[2] Univ Colorado, Ctr Canc, Aurora, CO USA

[3] Univ Med Ctr, Utrecht, Netherlands

[4] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6525 ED Nijmegen, Netherlands

[5] AstraZeneca, Macclesfield, Cheshire, England

来源：

CLINICAL CANCER RESEARCH | 2010年 / 16卷 / 05期

关键词：

KINASE; CI-1040; PATHWAY; GROWTH; POTENT; COLON;

D O I：

10.1158/1078-0432.CCR-09-2483

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: In part A, the aim was to define the maximum tolerated dose (MTD) of the hydrogen sulfate (Hyd-Sulfate) oral capsule formulation of the mitogen-activated protein kinase kinase inhibitor AZD6244 (ARRY-142886). In part B, the aim was to compare the pharmacokinetic profile of the new Hyd-Sulfate capsule with the initial AZD6244 free-base suspension and further characterize the pharmacodynamic profile and efficacy of the new formulation. Experimental Design: In part A, 30 patients received escalating doses of AZD6244 Hyd-Sulfate twice daily. In part B, 29 patients were randomized to a single dose of the Hyd-Sulfate capsule or free-base suspension, followed by a washout, then a single dose of the alternative formulation. Patients received the Hyd-Sulfate capsule twice daily at MTD of part A thereafter. Results: The MTD of the Hyd-Sulfate capsule was 75 mg twice daily. Dose limiting toxicities were Common Terminology Criteria for Adverse Events grade 3 acneiform rash and pleural effusion. Fatigue (65.7%) and acneiform dermatitis (60.0%) were the most frequent adverse events at the MTD. Based on area under curve(0-24), exposure of the 75 mg Hyd-Sulfate capsule relative to the 100 mg free-base suspension was 197% (90% confidence interval, 161-242%). Pharmacodynamic analysis showed that inhibition of 12-O-tetrade-canoylphorbol-13-acetate-induced extracellular signal-regulated kinase phosphorylation in peripheral blood lymphocytes was related to plasma concentrations of AZD6244, with an estimated IC50 of 352 ng/mL and maximum inhibition (E-max) of similar to 91%, showing target inhibition. A patient with metastatic melanoma bearing a V600E BRAF mutation achieved a complete response persisting after 15 months of therapy. Conclusions: The AZD6244 Hyd-Sulfate capsule formulation has shown a favorable toxicity, pharmacokinetic, and pharmacodynamic profile, and is being taken forward in ongoing clinical trials. Clin Cancer Res; 16(5); 1613-23. (C) 2010 AACR.

引用

页码：1613 / 1623

页数：11

共 16 条

[11]

LORUSSO P, 2007, AM ASS CANC RES NAT

[12]

Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI12807

[13] Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer [J].

Rinehart, J ;

Adjei, AA ;

LoRusso, PM ;

Waterhouse, D ;

Hecht, JR ;

Natale, RB ;

Hamid, O ;

Varterasian, M ;

Asbury, P ;

Kaldjian, EP ;

Gulyas, S ;

Mitchell, DY ;

Herrera, R ;

Sebolt-Leopold, JS ;

Meyer, MB .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) :4456-4462

[14] Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo [J].

Sebolt-Leopold, JS ;

Dudley, DT ;

Herrera, R ;

Van Becelaere, K ;

Wiland, A ;

Gowan, RC ;

Tecle, H ;

Barrett, SD ;

Bridges, A ;

Przybranowski, S ;

Leopold, WR ;

Saltiel, AR .

NATURE MEDICINE, 1999, 5 (07) :810-816

[15] Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) [J].

Tzekova, V. ;

Cebotaru, C. ;

Ciuleanu, T. E. ;

Damjanov, D. ;

Ganchev, H. ;

Kanarev, V. ;

Stella, P. J. ;

Sanders, N. ;

Pover, G. ;

Hainsworth, J. D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[16] Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor [J].

Yeh, Tammie C. ;

Marsh, Vivienne ;

Bernat, Bryan A. ;

Ballard, Josh ;

Colwell, Heidi ;

Evans, Ron J. ;

Parry, Janet ;

Smith, Darin ;

Brandhuber, Barbara J. ;

Gross, Stefan ;

Marlow, Allison ;

Hurley, Brian ;

Lyssikatos, Joe ;

Lee, Patrice A. ;

Winkler, James D. ;

Koch, Kevin ;

Wallace, Eli .

CLINICAL CANCER RESEARCH, 2007, 13 (05) :1576-1583

← 1 2 →